Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MiddleBrook Aims To Address $600 Million Strep Market With Moxatag

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.

You may also be interested in...



Advancis Gets Second Chance On Pulsatile Amoxicillin NDA

Firm plans to resubmit application with additional information in March.

Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA

Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.

Advancis Likely To Change Name Following Ruling In Favor Of Sanofi-Aventis

Court rules that Advancis name infringes on Sanofi-Aventis' trademark and orders the two firms to submit a proposed order by Oct. 23.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel